Alessandra Ferro

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino et al. · Journal of Thoracic Oncology · 2022 · 68 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +9

First-Line Osimertinib in Patients with <i>EGFR</i>-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

M. Lorenzi, Alessandra Ferro, Fabiana Letizia Cecere et al. · The Oncologist · 2021 · 62 citations · Full text

Medicine, Oncology, Pharmacology +15

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

Alessandra Ferro, G.M. Marinato, C. Mulargiu et al. · Critical Reviews in Oncology/Hematology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacology +16

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti et al. · Translational Lung Cancer Research · 2021 · 44 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience

Laura Bonanno, Alberto Pavan, Alessandra Ferro et al. · The Oncologist · 2020 · 28 citations · Full text

Medicine, Molecular Genetics, Oncology +12